MONTREAL, Canada, February 6 /PRNewswire/ --
- Shipment of Prion Capture Resin to MacoPharma in Q1 2008;
- MacoPharma Increased its Forecast for P-Capt(R) Filters Sale in 2008;
- Use of Affinity Prion Adsorbent for Plasma-Derived Products to Generate in Excess of CAD$25 M Over the Next 5 Years - CAD$4 M in 2008;
- 10th Product Approved by the FDA and or the EMEA, Contributing to Revenue Growth.
ProMetic Life Sciences Inc. (TSX:PLI) ("ProMetic") today provided an update on its business activities.